

SEQUENCE LISTING

5 <110> Nycomed Imaging AS

<120> Improvements in or relating to diagnostic/therapeutic
agents

10 <130> REF/Klaveness/993

<140> US 08/958,993

<141> 1997-10-28

15 <160> 25

<170> PatentIn Ver. 2.1

<210> 1

20 <211> 4

<212> PRT

<213> Artificial Sequence

<220>

25 <223> Description of Artificial
Sequence:RGDC-Mal-PEG3400-DSPE

<400> 1

Arg Gly Asp Cys

30 1

<210> 2

<211> 25

35 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide
comprising phosphatidylserine-binding and
heparin-binding sections

5

<400> 2

Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Ala Ala

1

5

10

15

10 Ala Trp Glu Pro Pro Arg Ala Arg Ile

20

25

<210> 3

15 <211> 8

<212> PRT

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:Heparin-binding
peptide

<400> 3

Trp Glu Pro Pro Arg Ala Arg Ile

25

1

5

<210> 4

<211> 6

30 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Linker sequence

35

<220>

<221> MOD_RES

<222> (1)

<223> MTX-phenylalanine

<400> 4

5 Phe Lys Leu Arg Leu Cys

1 5

<210> 5

10 <211> 4

<212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence:Heparin
sulphate binding peptide

<400> 5

20 Lys Arg Lys Arg

1

<210> 6

<211> 8

25 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fibronectin
30 peptide

<400> 6

Trp Gln Pro Pro Arg Ala Arg Ile

1 5

35

<210> 7

<211> 13
<212> PRT
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence:Lipopeptide
consisting of a heparin sulphate binding peptide
and a fibronectin peptide

10 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-lysine

15 <400> 7
Lys Lys Arg Lys Arg Trp Gln Pro Pro Arg Ala Arg Ile
1 5 10

20 <210> 8
<211> 24
<212> PRT
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence:Fibronectin
peptide sequence

<400> 8
30 Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Gly
1 5 10 15
Gly Trp Gln Pro Pro Arg Ala Ile
20

35

<210> 9

<211> 6
<212> PRT
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence:Biotinylated
endothelin-1 peptide

<220>
10 <221> MOD_RES
<222> (1)
<223> Biotin-D-Trp

<400> 9
15 Trp Leu Asp Ile Ile Trp
1 5

<210> 10
20 <211> 10
<212> PRT
<213> Artificial Sequence

<220>
25 <223> Description of Artificial Sequence:Biotinylated
fibrin-anti-polymerant peptide

<220>
28 <221> MOD_RES
30 <222> (1)
<223> Biotinylated-Gly

<220>
33 <221> MOD_RES
35 <222> (10)
<223> AMIDATION

<400> 10

Gly Pro Arg Pro Pro Glu Arg His Gln Ser

1

5

10

5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:Lipopeptide
containing RGD sequence and fluorescein reporter
group

15

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

20

<220>

<221> MOD_RES

<222> (4)

<223> Acetyl-RGD-K-fluorescein side chain

25

<400> 11

Lys Lys Lys Lys Gly

1

5

30

<210> 12

<211> 18

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:Endothelial

cell binding lipopeptide

<220>
<221> MOD_RES
5 <222> (1)
<223> 2-n-hexadecylstearyl-Lys

<220>
<221> MOD_RES
10 <222> (18)
<223> AMIDATION

<400> 12
Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys
15 1 5 10 15

Leu Ala

20
<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

25
<220>
<223> Description of Artificial Sequence:Lipopeptide
functionalised with captopril

30 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

35 <220>
<221> MOD_RES
<222> (4)

<223> Amide linked via side chain to captopril

<220>

5 <221> MOD_RES

5 <222> (4)

5 <223> AMIDATION

<400> 13

Lys Lys Lys Lys

10 1

15 <210> 14

15 <211> 13

15 <212> PRT

15 <213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:Lipopeptide

20 with an affinity for endothelial cells

<220>

25 <221> MOD_RES

25 <222> (1)

25 <223> Dipalmitoyl-Lys

<220>

30 <221> MOD_RES

30 <222> (4)

30 <223> Acp

<220>

35 <221> MOD_RES

35 <222> (13)

35 <223> AMIDATION

<400> 14

Lys Lys Lys Xaa Ile Arg Arg Val Ala Arg Pro Pro Leu

1

5

10

5 <210> 15

<211> 14

<212> PRT

<213> Artificial Sequence

10 <220>

<223> Description of Artificial Sequence:Lipopeptide
comprising an interleukin-1 receptor binding
peptide

15 <220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

20 <400> 15-

Lys Gly Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala

1

5

10

25 <210> 16

<211> 12

<212> PRT

<213> Artificial Sequence

30 <220>

<221> MOD_RES

<222> (1)

<223> Dabsyl-Tyr

35 <220>

<221> MOD_RES

<222> (10)

<223> RGDS chain linked via NH2 group of lysine

<220>

5 <223> Description of Artificial Sequence:Branched core
peptide comprising a dabsylated atherosclerotic
plaque-binding sequence and RGDS

<400> 16

Tyr Arg Ala Leu Val Asp Thr Leu Lys Lys Gly Cys

10 1 5 10

<210> 17

<211> 25

15 <212> DNA
<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:Synthetic
oligonucleotide

<220>

<221> misc_feature

<222> (1)

25 <223> Biotinylated

<400> 17

gaaaggtagt ggggtcgtgt gccgg

25

30

<210> 18

<211> 15

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:Lipopeptide

with affinity for thrombi

5 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

10 <220>
<221> MOD_RES
<222> (15)
<223> AMIDATION

15 <400> 18
Lys Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln
1 5 10 15

20 <210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence:Lipopeptide

30 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

35 <220>
<221> MOD_RES
<222> (5)
<223> Biotinylated-Lys

40 <400> 19
Lys Trp Lys Lys Lys Gly

1 5

5 <210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
10 <223> Description of Artificial
Sequence:Thiol-functionalised lipid molecule

15 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
20 <222> (4)
<223> Acp

25 <400> 20
Lys Lys Lys Xaa Cys
1 5

30 <210> 21
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
35 <223> Description of Artificial Sequence:Lipopeptide
functionalised with atenolol

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys
5
<220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked via amide bond to
10 atenolol

<220>
<221> MOD_RES
<222> (4)
15 <223> AMIDATION

<400> 21
Lys Lys Lys Lys
1
20

<210> 22
<211> 4
<212> PRT
25 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Lipopeptide
containing folic acid
30
<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys
35
<220>
<221> MOD_RES

<222> (4)

<223> AMIDATION

<220>

5 <221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to
folic acid

10 <400> 22

Lys Lys Lys Lys

1

15 <210> 23

<211> 4

<212> PRT

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence:Lipopeptide
containing a derivative of bestatin

<220>

25 <221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

<220>

30 <221> MOD_RES

<222> (4)

<223> AMIDATION

<220>

35 <221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to

derivative of bestatin

<400> 23

Lys Lys Lys Lys

5 1

<210> 24

<211> 4

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Lipopeptide
15 containing chlorambucil

<220>

<221> MOD_RES

<222> (1)

20 <223> Dipalmitoyl-Lys

<220>

<221> MOD_RES

<222> (4)

25 <223> AMIDATION

<220>

<221> MOD_RES

<222> (4)

30 <223> Lysine with side chain linked via amide bond to
chlorambucil

<400> 24

Lys Lys Lys Lys

35 1

<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:Lipopeptide
functionalised with sulfisoxazole

10 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

15 <220>
<221> MOD_RES
<222> (4)
<223> AMIDATION

20 <220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked via amide bond to
sulfisoxazole

25 <400> 25
Lys Lys Lys Lys
1

30 <210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

<400> 26

Tyr Arg Ala Leu Val Asp Thr Leu Lys

1

5

5

<210> 27

<211> 16

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

15

<400> 27

Tyr Ala Lys Phe Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr

1

5

10

15

20

<210> 28

<211> 17

<212> PRT

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

<400> 28

30 Arg Ala Leu Val Asp Thr Glu Phe Lys Val Lys Gln Glu Ala Gly Ala

1

5

10

15

Lys

35

<210> 29

<211> 14
<212> PRT
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence:Thrombus
binding peptide

<400> 29
10 Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln
1 5 10

15 <210> 30
<211> 4
<212> PRT
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence:Thrombus
binding peptide

<400> 30
Gly Pro Arg Gly
25 1

30 <210> 31
<211> 13
<212> PRT
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence:Platelet
binding peptide

<400> 31

Pro Leu Tyr Lys Lys Ile Ile Lys Lys Leu Leu Glu Ser

1

2

10

5

10

15

故其後人之爲詩者，皆以爲子雲之子，故其後人之爲詩者，皆以爲子雲之子。